Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.8
5.6
Journals
IJMS
Special Issues
Cancer Cell Metabolism: New Advances and Potential Therapies
ijms-logo
Submit to Special Issue Submit Abstract to Special Issue Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Cancer Cell Metabolism: New Advances and Potential Therapies

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: 30 September 2024 | Viewed by 1069

Special Issue Editors

Dr. Odília Queirós

E-Mail Website
Guest Editor
UNIPRO—Oral Pathology and Rehabilitation Research Unit, University Institute of Health Sciences, CESPU, CRL, 4585-116 Gandra, Portugal
Interests: cancer cell metabolism; multidrug resistance in cancer cells; Pgp activity; pH regulators in cancer; new anticancer drugs
Special Issues, Collections and Topics in MDPI journals
Dr. Maria de Fátima Monginho Baltazar

E-Mail Website
Guest Editor
1. School of Medicine, University of Minho, 4710-057 Braga, Portugal
2. ICVS/3B’s PT Government Associate Laboratory, 4710-057 Braga, Portugal
Interests: cancer glycolytic metabolism; new metabolic biomarkers in cancer; cancer drug resistance; drug discovery in cancer
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cancer cell metabolism is one of the most emergent and promising fields of study in cancer research. The metabolic switch that occurs in cancer cells is associated with cancer aggressiveness and can be considered the Achilles heel of cancer, offering a powerful opportunity for new cancer therapy strategies. This Special Issue intends to assemble the most recent advances in this field, aiming at exploring the intricate mechanisms of the reprogrammed metabolism in cancer cells, as well as the development of innovative strategies for cancer therapy by exploiting this cancer hallmark. Comprehensive reviews and original research manuscripts describing specific studies on new therapeutic approaches, namely the development of new molecules that can act on metabolic targets, but also the influence of cancer metabolism on the tumor microenvironment, the role of key enzymes or metabolites on cancer growth, or the interconnection of this field with other emergent therapies, like immunotherapy, are welcome.

Dr. Odília Queirós
Dr. Maria de Fátima Monginho Baltazar
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

 

Keywords

  • Warburg effect
  • reprogrammed metabolism in cancer
  • metabolic targets
  • combined anticancer therapy
  • metabolic modulator drugs

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

18 pages, 7026 KiB  
Article
ERK5 Interacts with Mitochondrial Glutaminase and Regulates Its Expression
by Yolanda María Guillén-Pérez, María Jesús Ortiz-Ruiz, Javier Márquez, Atanasio Pandiella and Azucena Esparís-Ogando
Int. J. Mol. Sci. 2024, 25(6), 3273; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms25063273 - 14 Mar 2024
Viewed by 588
Abstract
Many of the biological processes of the cell, from its structure to signal transduction, involve protein–protein interactions. On this basis, our aim was to identify cellular proteins that interact with ERK5, a serine/threonine protein kinase with a key role in tumor genesis and [...] Read more.
Many of the biological processes of the cell, from its structure to signal transduction, involve protein–protein interactions. On this basis, our aim was to identify cellular proteins that interact with ERK5, a serine/threonine protein kinase with a key role in tumor genesis and progression and a promising therapeutic target in many tumor types. Using affinity chromatography, immunoprecipitation, and mass spectrometry techniques, we unveiled an interaction between ERK5 and the mitochondrial glutaminase GLS in pancreatic tumor cells. Subsequent co-immunoprecipitation and immunofluorescence studies supported this interaction in breast and lung tumor cells as well. Genetic approaches using RNA interference techniques and CRISPR/Cas9 technology demonstrated that the loss of ERK5 function led to increased protein levels of GLS isoforms (KGA/GAC) and a concomitant increase in their activity in tumor cells. It is well known that the tumor cell reprograms its intermediary metabolism to meet its increased metabolic needs. In this sense, mitochondrial GLS is involved in the first step of glutamine catabolism, one of the main energy sources in the context of cancer. Our data suggest that ERK5 contributes to the regulation of tumor cell energy metabolism via glutaminolysis. Full article
(This article belongs to the Special Issue Cancer Cell Metabolism: New Advances and Potential Therapies)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop